Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 4/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.40 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.37 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.37 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.37 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3086556 | 0.82 | CSF1R (0.55) | CSF1RMAP4K4HDAC1HDAC2HDAC3 | |
| SCHEMBL21988028 | 0.82 | CSF1R (0.44) | CSF1RMAP4K4PIK3CDHDAC1HDAC2 | |
| SCHEMBL16387219 | 0.82 | HDAC2 (0.52) | HDAC1HDAC2HDAC3 | |
| SCHEMBL3083333 | 0.81 | CYP11B1 (0.50) | CSF1RPIK3CDCYP1A2HDAC1HDAC2 | |
| SCHEMBL3096261 | 0.81 | CSF1R (0.46) | CSF1RHDAC1HDAC2HDAC3TDP1 | |
| SCHEMBL3083133 | 0.80 | KDR (0.48) | CSF1RHDAC1HDAC2HDAC3KDR | |
| SCHEMBL3096089 | 0.80 | PTGS2 (0.43) | CSF1RHDAC1HDAC2HDAC3TDP1 | |
| SCHEMBL13180457 | 0.78 | HDAC1 (0.41) | CSF1RHDAC1HDAC2HDAC3PSMB5 | |
| SCHEMBL25343832 | 0.77 | PIK3CD (0.48) | CSF1RMAP4K4PIK3CDKCNH2HDAC1 | |
| SCHEMBL3089993 | 0.76 | CSF1R (0.50) | CSF1RPIK3CDCYP1A2HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790724-B2 | c-fms kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-09-07 | — | — | US | claimed |
| EP-2016057-A1 | C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-21 | — | — | EP | claimed |
| WO-2007123516-A1 | C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-11-01 | — | — | WO | claimed |
| US-20060258666-A1 | c-fms kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-16 | — | — | US | claimed |
| US-7790724-B2 | c-fms kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-09-07 | — | — | US | disclosed |
| EP-2016057-A1 | C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-21 | — | — | EP | disclosed |
| WO-2007123516-A1 | C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-11-01 | — | — | WO | disclosed |
| US-20060258666-A1 | c-fms kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258666-A1 | c-fms kinase inhibitors | FLT3, FES, FER | CSF1R 111/4885MAP4K4 182/4885PIK3CD 1091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.